Livres Compléments alimentaires
Le Pycnogénol protége les reins
L’hypertension affecte de nombreux sportifs de force. Le Pycnogénol contribue à les protéger.
Kidney flow and function in hypertension: protective effects of pycnogenol in hypertensive participants—a controlled study.
J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):41-6. Cesarone MR, Belcaro G, Stuard S, Schönlau F, Di Renzo A, Grossi MG, Dugall M, Cornelli U, Cacchio M, Gizzi G, Pellegrini L.
This study evaluated the effects of Pycnogenol as an adjunct to angiotensin-converting enzyme (ACE)-inhibitor ramipril treatment of hypertensive patients presenting with early signs of renal function problems. One group of 26 patients was medicated with 10 mg ramipril per day only; a second group of 29 patients took Pycnogenol in addition to the ACE inhibitor over a period of 6 months. At trial end, a lowered systolic and diastolic blood pressure was found in both groups, with a significant further reduction of diastolic pressure in the group given Pycnogenol in addition to ramipril. The major aim of this study was the investigation of kidney-protective effects of Pycnogenol. Urinary albumin decreased from 87 +/- 23 to 64 +/- 16 mg/d with ramipril only. Additional Pycnogenol lowered albumin significantly better from 91 +/- 25 to 39 +/- 13 mg/day (P
< .05). In both groups, serum creatinine was lowered; however, only in the combination treatment group did the effect reached statistical significance. In both groups, CRP levels decreased from 2.1 to 1.8 with ramipril and from 2.2 to 1.1 with the ramipril-Pycnogenol combination; the latter reached statistical significance. Kidney cortical flow velocity was investigated by Doppler color duplex ultrasonography. Both systolic and diastolic flow velocities increased significantly after 6 months medication with ramipril. The addition of Pycnogenol to the regimen statistically significantly further enhanced kidney cortical flow velocities, by 8% for diastolic flow and 12% for systolic flow, relative to values found for the group taking ramipril only. The
protective effects of Pycnogenol for initial kidney damage found in this study warrant further research with a larger number of patients and over a longer period of time.
Les oméga-3 protègent les reins
La musculation abaisse temporairement la fonction rénale. Les oméga-3 produisent l’effet inverse sur la protéinurie.
The effect of n–3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials
Am J Clin Nutr 2009;89:1937–45.
Edgar R Miller III, Stephen P Juraschek, Lawrence J Appel, Madhavi Madala, Cheryl AM Anderson, Joachim Bleys, and Background: Chronic kidney disease is a major worldwide problem. Although epidemiologic and experimental studies suggest that n–3 long-chain polyunsaturated fatty acid (n–3 LCPUFA) supplementation may prevent or slow the progression of kidney disease, evidence from clinical trials is inconsistent.
Objective: The objective was to combine evidence from controlled clinical trials to assess the effect of n–3 LCPUFA supplementation on the change in urine protein excretion (UPE) and on glomerular filtration rate (GFR).
Design: We performed a meta-analysis of clinical trials that tested the effect of n–3 LCPUFA supplementation on UPE, a marker of kidney damage, and on GFR, a marker of kidney function. A randomeffects model was used to pool SD effect size (Cohen’s d) across studies.
Results: Seventeen trials with 626 participants were included in the meta-analysis. Most trials focused on patients with a single underlying diagnosis: IgA nephropathy (n ¼ 5), diabetes (n ¼ 7), or lupus nephritis (n ¼ 1). The dose of n–3 LCPUFAs ranged from 0.7 to 5.1 g/d, and the median follow-up was 9 mo. In the pooled analysis, there was a greater reduction in UPE in the n–3 LCPUFA group than in the control group: Cohen’s d for all trials was 20.19 (95% CI: 20.34, 20.04; P ¼ 0.01). In a patient with 1 g UPE/d , this corresponds to a reduction of 190 mg/d. Effects on GFR were reported in 12 trials. The decline in GFR was slower in the n–3 LCPUFA group than in the control group, but this effect was not significant (0.11; 95% CI: 20.07, 0.29; P ¼ 0.24).
Conclusions: In our meta-analysis, use of n–3 LCPUFA supplements reduced UPE but not the decline in GFR. However, small numbers of participants in trials, different methods of assessing proteinuria and GFR, and inconsistent data reporting limit the strength of these conclusions. Large, high-quality trials with clinical outcomes are warranted.
Guide des boosters sexuels, pour bientôt
Le Guide des boosters sexuels : Compléments alimentaires et médicaments : sortie prévue le mois prochain.
